Recent advances in the molecular characterization of childhood brain tumors: Editorial comments

Brain Pathology

Volumn 7, Issue 2, 1997, Pages 753-754

  Pollack, Ian F ^a   Becker, Laurence E ^b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN TUMOR; CHILD; CHILDHOOD; CONFERENCE PAPER; HUMAN; NEUROECTODERM TUMOR;

EID: 0030972141     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.1997.tb01061.x     Document Type: Conference Paper

References (82)

1. Alderson LM, Castleberg RL, Harsh GR, Louis DN, Henson JW (1995) Human gliomas with wild-type p53 express bcl-2 Cancer Res 55: 999-1001
2. Bogler O, Huang H-JS, Cavenee WK (1995) Loss of wild- type p53 bestows a growth advantage on primary cortical astrocytes and facilitates their in vitro transformation. Cancer Res 55: 2746-2751
3. Burger PC, Green SB (1987) Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 59: 1617-1625
4. Burger PC, Vogel FS, Green SB, Strike TA (1985) Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications. Cancer 56: 1106-1111
5. Cho Y, Gorina S, Jeffrey PD, Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumongenic mutations. Science 265: 346- 355
6. Chung RY, Whaley J, Kley N, Anderson K, Louis DN, Menon A, Hettlich C, Freiman R, Hedley-Whyte ET, Martuza R, Jenkins R, Yandell D, Seizmger BR (1991) TP53 mutation and chromosome 17p deletion in human astrocytomas. Genes Chromosom Cancer 3: 323-331
7. Debbas M, White E (1993) Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Develop 7: 546-554
8. Dreyling MH, Bohlander SK, Adeyanju MO, Olopade OI (1995) Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization. Cancer Res 55: 984-988
9. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Petterson RF, Collins VP (1991) Genes for epidermal growth factor receptor, transforming growth factor a, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51: 2164-2172
10. Eng C, Li FP, Abramson OH, Ellsworth RM, Wong FL, Goldman MB, Seddon J, Tarbell N, Boice JD (1993) Mortality from second tumors amoung long-term survivors of retinoblastoma. J Natl Cancer Inst 85: 1121- 1128
11. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU (1992) Amplification and/or over- expression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors Cancer Res 52: 4550-4553
12. Fuits D, Pedone C (1993) Deletion mapping of the long arm of chromosome 10 in ghoblastoma multiforme Genes Chromosom Cancer 7: 173-7
13. Fults D, Pedone CA, Thomas GA, White R (1990) Allelotype of human malignant astrocytoma Cancer Res 50: 5784-5789
14. Fults D, Petronio J, Noblett BD, Pedone CA (1992) Chromosome 11p15 deletions in human malignant astro- cytomas and primitive neuroectodermal tumors Genomics 14: 799-801
15. Giani C, Finocchiaro G (1994) Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res 54: 6338- 6339
16. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY (1993) Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells, a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4: 121-33
17. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giacca AJ (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379: 88-91
18. INK4 or retinoblastoma protein (pRb). or amplification-associated overexpression of CDK4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 55: 4833-4836
19. Heldin C-H (1992) Structural and functional studies on platelet-derived growth factor. EMBO J 11: 4251-4259
20. Henson JW, Schnitker BL, Correa KM, von Deimling A, Fassbender F, Xu H-J, Benedict WF, Yandell DW, Louis DN (1994) The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol 36: 714- 721
21. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin C-H, Westermark B, Nister M (1992) Platelet- derived growth factor and its receptors in human glioma tissue expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52: 3213-3219
22. Hermanson M, Funa K, Westermark B, Heldin C-H, Wiestler OD, Louis DN, von Deimling A, Nister M (1996) Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor a receptor expression in human malignant gliomas. Cancer Res 56: 164-171
23. Hoang-Xuan K, Merel P, Vega F, Hugot JP, Cornu P, Delattre JY, Poisson M, Thomas G, Delattre O (1995) Analysis of the NF2 tumor-suppressor gene and of chromosome 22 deletions in gliomas Int J Canc 60: 478-481
24. 23a. Hsu SC, Volpert OV, Steck PA, Mikkelson T, Polverini PJ, Rao S, Chou P, Bouck NP (1996) Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1 Canc Res 56: 5684-5691
25. Ichimura K, Schmidt EE, Goike HM, Collins VP (1996) Human glioblastomas with no alterations of the CDKN2 (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the rettnoblastoma gene Oncogene 13: 1065- 1072
26. James CD, Carlblom E, Dumanski JP, Hansen M, Nordenskjold M, Collins VP, Cavenee WK (1988) Clonal genomic alterations in glioma malignancy stages. Cancer Res 48: 5546-5551
27. Jen J, Harper W, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S. Willson JKV, Kmzler KW, Vogelstein B (1994) Deletion of p16 and p15 genes in brain tumors. Cancer Res 54: 6353-6358
28. WAF1/Cip1 in human brain tumors Oncogene 11: 2021-2028
29. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, Johnson BE, Skolnick MH (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440
30. Karlbom AE, James CD, Boethius J, Cavenee WK, Collins VP, Nordenskjoid M, Larsson C (1993) Loss of heterozygosity in malignant ghomas involves at least three distinct regions on chromosome 10. Hum Genet 92: 169-174
31. Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer Cell 87: 159-170
32. Kinzler KW, Vogelstein B (1996) Life (and death) in a malignant tumor. Nature 379: 19-20
33. Koh J, Enders GH, Dynlacht BD, Harlow E (1995) Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375: 506-510
34. Koopman J, Maintz D, Schild S, Schramm J, Louis DN, Wiestler OD, von Deimling A (1995) Multiple polymorphisms, but no mutations, in the WAF1/CIP1/CDKN1 gene in human brain tumors. Brit J Cancer 72: 1230-1233
35. Leenstra S, Bijlsma EK, Troost D, Oosting J, Westerveld A, Bosch DA, Hulsebos TJM (1994) Allele loss on chromosomes 10 and 17p and epidermal growth factor receptor gene amplification in human malignant astrocytoma related to prognosis. Br J Canc 70: 684-689
36. Louis DM (1994) The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53: 11-21
37. Louis DN, Cavenee WK (1997) Molecular biology of central nervous system tumors In: Cancers: Principles and Practice of Oncology, DeVita VT, Hellman S, Rosenberg SA (eds.), Lippincott-Raven Publishers: Philadephia
38. Louis DN, Gusella JF (1995) A tiger behind many doors: multiple genetic pathways to malignant glioma. Trends Genet 11: 412-415
39. Lowe SW, Ruley HE (1993) Stabilization of the p53 tumor suppressor is induced by adenovirus 5 EIA and accompanies apoptosis Genes Develop 7: 535-545
40. INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res 55: 4818-4823
41. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J (1995) Retinoblastoma- protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375: 503-506
42. INK4A Transcript. Cancer Res 55: 2995-2997
43. ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA 92: 6289-6293
44. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D (1995) 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1. Nature Med 1: 686-692
45. Moulton T, Samara G, Chung W, Yuan L, Desai R, Sisti M, Bruce J, Tycko B (1995) MTS1/pl6/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 146: 613- 619
46. Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, Huang H-JS (1996) A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56: 5079-5086
47. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756
48. Ono Y, Tamiya T, Ichikawa T, Matsumoto K, Furuta T, Ohmoto T, Akiyama K, Seki S, Ueki K, Louis DN (1997) Accumulation of wild Type p53 in astrocytomas is regionally heterogeneous and associated with increased p21 expression. Acta Neuropathol (in press)
49. Ono Y, Tamiya T, Ichikawa T, Kunishio K, Mtsumoto K, Furuta T, Ohmoto T, Ueki K, Louis DN (1996) Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. J Neuropathol Exp Neurol 55: 1026-1031
50. Pilkington GJ (1994) Tumour cell migration in the central nervous system. Brain Pathol 4: 157-166
51. Plate KH, Breier G, Risau W (1994) Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 4: 207-218
52. Quelle DE, Zindy F, Ashmun RA, Sherr CJ (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of cell cycle arrest. Cell 83: 993-1000
53. Rasheed BKA, Fuller GN, Friedman AH, Bigner DD, Bigner SH (1992) Loss of heterozygosity for 10q loci in human gliomas. Genes Chromosom Cancer 5: 75-82
54. Rasheed BKA, McLendon RE, Friedman HS, Friedman AH, Fuchs HE, Bigner DD, Bigner SH (1995) Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene 10: 2243- 2246
55. Rasheed BKA, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD, Bigner SH (1994) Alterations of the TP53 gene in human gliomas. Cancer Res 54: 1324- 1330
56. Rerfenberger G, Ichimura K, Reifenberger J, Elkahloun AG, Meltzer PS, Collins VP (1996) Refined mapping of 12q13-q15 amplicons in malignant gliomas suggests CD/C4/SAS and MDM2 as independent amplification targets. Cancer Res 56: 5141-5145
57. Rerfenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP (1993) Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53: 2736-2739
58. Reifenberger G, Reifenberger J, Ichimura K, Melzter PS, Collins VP (1994) Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 54: 4299-4303
59. Reifenberger J, Ring GU, Gies U, Cobbers JMJL, Oberstrab J, An H-X, Niederacher D, Wechsler W, Reifenberger G (1996) Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 55: 822-831
60. Rey JA, Bello MJ, Jiménez-Lara AM, Vaquero J, Kusak ME, de Campos JM, Sarasa JL, Pestan̄a A (1992) Loss of heterozygosity for distal markers on 22q in human gliomas. Int J Cancer 51: 703-706
61. Rosenberg JE, Lisle DK, Burwick JA, Ueki K, von Deimling A, Mohrenweiser HW, Louis DN (1996) Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. Oncogene 13: 2483-2485
62. Rubio M-P, Correa KM, Ramesh V, MacCollin MM, Jacoby LB, von Deimling A, Gusella JF Louis DN (1994) Analysis of the neurofibromatosis 2 (NF2) gene in human ependymomas and astrocytomas Cancer Res 54: 45-47
63. Rubio M-P, Correa KM, Ueki K, Mohrenweiser HW, Gusella JF, von Deimling A, Louis DN (1994) The putative glioma tumor suppressor gene on chromosome 19q maps between APOC2 and HRC. Cancer Res 54: 4760- 4763
64. Rubio M-P, von Deimling A, Yandell DW, Wiestler OD, Gusella JF, Louis DN (1993) Accumulation of wild-type p53 protein in human astrocytomas. Cancer Res 53: 3465-3467
65. Schmidt EE, Ichimura K, Reifenberger G, Collins VP (1994) CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54: 6321-6324
66. Seizinger BR, Klinger HP, Junien C, Nakamura Y, Le Beau M, Cavenee W, Emanuel B, Ponder B, Naylor S, Mitelman F, Louis DN, Menon A, Newsham I, Decker J, Kaelbing I, Henry I, von Deimling A (1991) Report of the committee on chromosome and gene loss in human neoplasia Cylogenet Cell Genet 58: 1080-1096
67. Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/cdk4. Nature 366: 704-707
68. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum M, Cavenee W, Vogelstein B (1992) Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature 355: 846-847
69. Sonoda Y, Iizuka M, Yasuda J, Makino R, Ono T, Kayama T, Yoshimoto T, Sekiya T (1995) Loss of heterozygosity at 11p15 in malignant glioma Cancer Res 55: 2166-2163
70. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A (1995) Complex Structure and Regulation of the p 16 (MTS1) Locus. Cancer Res 55: 2988-2994
71. Ueki K, Ono Y, Henson JW, von Deimling A, Louis DN (1996) CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56: 150-153
72. Ueki K, Ramaswamy S, Billings SJ, Mohrenweiser HW, Louis DN (1997) ANOVA, a putative astrocytic RNA-binding protein gene that maps to chromosome 19q13.3. Neurogenetics (in press)
73. Ueki K, Rubio M-P, Ramesh V, Correa KM, Rutter JL, von Deimling A, Buckler AJ, Gusella JF, Louis DN (1994) MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Molec Genet 3: 1841-1845
74. von Deimling A, Louis DN, von Ammon K, Petersen I, Hoell T, Chung RY, Martuza R, Schoenfeld D, Yasargil MG, Wiestier OD, Seizinger BR (1992) Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme J Neurosurg 77: 295-301
75. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN (1993) Subsets of glioblastoma multiforme defined by molecular genetic analysis Brain Pathol 3: 19-26
76. Walker DG, Duan W, Popovic EA, Kaye AH, Tomlinson FH, Lavin M (1995) Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res 55: 20-23
77. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas Brain Parhol 6: 217-223
78. White E (1996) Life, death and the pursuit of apoptosis. Genes Devel 10: 1-15
79. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B (1987) Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84: 6899-6903
80. Yahanda AM, Bruner JM, Donehower LA, Morrison RS (1995) Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas. Molec Cell Biol 15: 4249-4259
81. Yong WH, Chou D, Ueki K, Harsh GR, von Deimling A, Gusella JF, Mohrenweiser HW, Louis DN (1995) Chromosome 19q deletions in human gliomas overlap telomeric to D19S219 and may target a 425 kb region centromeric to D19S112. J Neuropathol Exp Neurol 54: 622-626
82. Yong WH, Ueki K, Chou D, Reeves SA, von Deimling A, Gusella JF, Mohrenweiser HW, Buckler AJ, Louis DN (1995) Cloning of a highly conserved human protein serine threonine phosphatase gene from the glioma candidate region on chromosome 19q13.3. Genomics 29: 533- 536